IRRAS Announces Changed Publication Date for the Q1 2022 Interim Report
, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care,
IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.
IRRAS is listed on Nasdaq Stockholm (ticker: IRRAS).
Director, Investor Relations
+46 102 11 5172
The information was released for public disclosure, through the agency of the contact person above, on April 25, 2022, at 8:30 (CET).